June 26, 2017 06:45 AM EDT
R&D

Seat­tle Ge­net­ics gets a PhI­II win for Ad­cetris, but shares slide as frets linger

John Carroll

Editor & Founder

Seat­tle Ge­net­ics $SGEN has had a rough Q2 as its lead ex­per­i­men­tal ther­a­py was put back on hold, forc­ing in­ves­ti­ga­tors to scrap Phase III short­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work

Mer­ck­'s Keytru­da com­bo miss­es over­all sur­vival in Phase 3 tri­al in ovar­i­an can­cer

Pad­lock share­hold­ers sue Bris­tol My­ers over mile­stone dis­pute af­ter 2016 ac­qui­si­tion

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times